Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT I HADDAD

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1942259098
CMS profile
88160
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$111,352.45

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT I HADDAD

NPI 1942259098 · CMS profile ID 88160

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942259098?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT I HADDAD, NPI 1942259098, CMS profile ID 88160. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942259098?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ROBERT I HADDAD, NPI 1942259098, CMS profile ID 88160. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942259098?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ROBERT I HADDAD, NPI 1942259098, CMS profile ID 88160, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1942259098?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $111,352.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $58.0006/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218802289 CMS
Exelixis Inc. $9,337.2406/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1218802281 CMS
E.R. Squibb & Sons, L.L.C. $125.9205/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184518487 CMS
E.R. Squibb & Sons, L.L.C. $15.5405/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184518489 CMS
ABBVIE INC. $68.0005/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201986935 CMS
GlaxoSmithKline, LLC. $52.4105/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190625614 CMS
GlaxoSmithKline, LLC. $190.6305/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190568248 CMS
Merck Sharp & Dohme LLC $8,960.0005/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1237994832 CMS
Merck Sharp & Dohme LLC $150.0005/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238002150 CMS
Merck Sharp & Dohme LLC $32.0105/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238001200 CMS
Merck Sharp & Dohme LLC $44.8905/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238002350 CMS
Merck Sharp & Dohme LLC $29.9305/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238033418 CMS
Merck Sharp & Dohme LLC $215.7005/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238038840 CMS
Merck Sharp & Dohme LLC $215.7005/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1237998046 CMS
Merck Sharp & Dohme LLC $67.8405/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237999206 CMS
Merck Sharp & Dohme LLC $69.8505/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238010724 CMS
Merck Sharp & Dohme LLC $215.7005/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1237998048 CMS
Merck Sharp & Dohme LLC $7,360.9105/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1237998790 CMS
Merck Sharp & Dohme LLC $5,760.0005/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238036260 CMS
Merck Sharp & Dohme LLC $150.0005/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238040337 CMS
Genmab U.S., Inc. $8,090.6805/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1235925837 CMS
GlaxoSmithKline, LLC. $31.4104/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190404935 CMS
GlaxoSmithKline, LLC. $620.8304/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190460880 CMS
Merck Sharp & Dohme LLC $183.0704/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238269276 CMS
AstraZeneca UK Limited $2,460.0004/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211398780 CMS
Boehringer Ingelheim International GmbH $740.0003/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1215873473 CMS
AstraZeneca Pharmaceuticals LP $1,370.0002/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1214772817 CMS
Genmab U.S., Inc. $30.8301/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235925833 CMS
Merck Sharp & Dohme LLC $1,220.0001/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238039396 CMS
Janssen Pharmaceuticals, Inc $705.0001/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174533703 CMS
Janssen Scientific Affairs, LLC $881.2501/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174170514 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $67,513.38 65
PY2020 $43,510.45 24
PY2021 $24,555.28 13
PY2022 $52,842.35 39
PY2023 $84,049.87 56
PY2024 $67,524.52 26
PY2025 $111,352.45 81

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,720.29 1
PY2025 Principal investigator $967,878.05 66
PY2024 Recipient $44,959.22 13
PY2024 Principal investigator $593,712.39 44
PY2023 Principal investigator $745,226.54 127
PY2022 Principal investigator $685,220.86 18
PY2021 Principal investigator $613,536.37 25
PY2020 Principal investigator $176,630.74 53
PY2019 Recipient $5,732.00 1
PY2019 Principal investigator $293,247.83 69

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,500.03 12/31/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE, INC
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185546601
Principal investigator 1 Merck Sharp & Dohme LLC $7,436.54 12/31/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected populati No dispute reported 06/30/2026 1232917493
Principal investigator 1 Merck Sharp & Dohme LLC $17,540.72 12/31/2025 Non-covered Recipient Entity
Dana Farber Cancer Center
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1232927059
Principal investigator 1 Incyte Corporation $715.50 12/24/2025 Non-covered Recipient Entity
Dana Farber Mass General Brigham Cancer Care Inc
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520917
Principal investigator 1 Aveo Pharmaceuticals, Inc. $40,090.19 12/09/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199911317
Principal investigator 1 Incyte Corporation $18,246.00 11/24/2025 Non-covered Recipient Entity
Dana Farber Mass General Brigham Cancer Care Inc
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520926
Principal investigator 1 Incyte Corporation $34,450.00 11/24/2025 Non-covered Recipient Entity
Dana Farber Mass General Brigham Cancer Care Inc
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520930
Principal investigator 1 Aveo Pharmaceuticals, Inc. $77,244.68 11/20/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199911319
Principal investigator 1 Incyte Corporation $8,677.00 11/06/2025 Non-covered Recipient Entity
Dana Farber Mass General Brigham Cancer Care Inc
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520922
Principal investigator 1 Incyte Corporation $8,677.00 10/30/2025 Non-covered Recipient Entity
Dana Farber Mass General Brigham Cancer Care Inc
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520913
Principal investigator 1 Merck Sharp & Dohme LLC $93,575.68 10/22/2025 Non-covered Recipient Entity
Dana Farber , Mass General Brigham Cancer Care, Inc
Phase II, multi cohort trial of neoadjuvant and post surgery IO102 IO103 and pembrolizumab in patients with selected resectable tumors No dispute reported 06/30/2026 1232932165
Principal investigator 1 Aveo Pharmaceuticals, Inc. $17,603.29 10/08/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199911315
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,575.00 10/08/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199911321
Principal investigator 1 Exelixis Inc. $3,000.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380458
Principal investigator 1 Exelixis Inc. $2,500.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380460
Principal investigator 1 Exelixis Inc. $8,500.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380462
Principal investigator 1 Exelixis Inc. $2,500.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380464
Principal investigator 1 Exelixis Inc. $10,000.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380466
Principal investigator 1 Exelixis Inc. $3,000.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380468
Principal investigator 1 Exelixis Inc. $1,000.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380470
Principal investigator 1 Exelixis Inc. $1,350.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380472
Principal investigator 1 Exelixis Inc. $4,000.00 10/02/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222380474
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/25/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192135635
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 09/25/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192135645
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/25/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192140514
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/25/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192140526
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/25/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192140543
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/25/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192140555
Principal investigator 1 Aveo Pharmaceuticals, Inc. $26,911.90 09/10/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911289
Principal investigator 1 Aveo Pharmaceuticals, Inc. $53,327.63 09/10/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911299
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 09/02/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192135640
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 09/02/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192135652
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 09/02/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192135660
Principal investigator 1 GlaxoSmithKline, LLC. $450.00 09/02/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192140521
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 09/02/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192140530
Principal investigator 1 GlaxoSmithKline, LLC. $450.00 09/02/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192140536
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 09/02/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192140548
Principal investigator 1 Aveo Pharmaceuticals, Inc. $21,042.00 08/06/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911301
Principal investigator 1 Merck Sharp & Dohme LLC $18,230.40 07/31/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected populati No dispute reported 06/30/2026 1232917491
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,697.29 07/25/2025 Non-covered Recipient Entity
DANA FARBER PARTNERS CANCER CARE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185546599
Principal investigator 1 Aveo Pharmaceuticals, Inc. $36,342.20 07/16/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911291
Principal investigator 1 Aveo Pharmaceuticals, Inc. $26,640.73 07/09/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911303
Principal investigator 1 Aveo Pharmaceuticals, Inc. $48,918.12 06/20/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911311
Principal investigator 1 AstraZeneca Pharmaceuticals LP $56,007.03 06/04/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC.
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185546603
Principal investigator 1 Incyte Corporation $13,354.00 05/22/2025 Non-covered Recipient Entity
DANA-FARBER CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520427
Principal investigator 1 Aveo Pharmaceuticals, Inc. $33,223.50 05/13/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911305
Principal investigator 1 Aveo Pharmaceuticals, Inc. $24,248.14 05/13/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911313
Principal investigator 1 Incyte Corporation $25.02 05/08/2025 Non-covered Recipient Entity
DANA-FARBER CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520431
Principal investigator 1 Aveo Pharmaceuticals, Inc. $875.00 04/17/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911307
Principal investigator 1 Incyte Corporation $9,297.90 04/17/2025 Non-covered Recipient Entity
DANA-FARBER CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520423
Principal investigator 1 Aveo Pharmaceuticals, Inc. $17,481.75 04/11/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911309
Recipient F. Hoffmann-La Roche AG $1,720.29 03/31/2025 Covered Recipient Physician Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer No dispute reported 06/30/2026 1211538583
Principal investigator 1 Aveo Pharmaceuticals, Inc. $20,840.31 03/19/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911297
Principal investigator 1 Genentech, Inc. $18,010.00 03/14/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer No dispute reported 06/30/2026 1211593800
Principal investigator 1 Genentech, Inc. $2,566.00 03/14/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer No dispute reported 06/30/2026 1211593804
Principal investigator 1 Genentech, Inc. $10,300.00 03/14/2025 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
Atezolizumab versus placebo as adjuvant therapy in locally advanced head and neck cancer No dispute reported 06/30/2026 1211593807
Principal investigator 1 Aveo Pharmaceuticals, Inc. $700.00 03/06/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911287
Principal investigator 1 Incyte Corporation $18,246.00 02/27/2025 Non-covered Recipient Entity
Dana Farber Mass General Brigham Cancer Care Inc
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520905
Principal investigator 1 Incyte Corporation $10,659.60 02/13/2025 Non-covered Recipient Entity
Dana Farber Mass General Brigham Cancer Care Inc
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520909
Principal investigator 1 Aveo Pharmaceuticals, Inc. $875.00 02/05/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911285
Principal investigator 1 Aveo Pharmaceuticals, Inc. $29,769.36 02/05/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911295
Principal investigator 1 Merck Sharp & Dohme LLC $1,153.40 02/05/2025 Non-covered Recipient Entity
Dana Farber Cancer Center
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1232926885
Principal investigator 1 Aveo Pharmaceuticals, Inc. $8,597.10 01/22/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911283
Principal investigator 1 Incyte Corporation $12,789.90 01/16/2025 Non-covered Recipient Entity
Dana Farber Mass General Brigham Cancer Care Inc
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520902
Principal investigator 1 Incyte Corporation $75.06 01/09/2025 Non-covered Recipient Entity
DANA-FARBER/ MASS GENERAL
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520843
Principal investigator 1 Incyte Corporation $100.08 01/09/2025 Non-covered Recipient Entity
DANA-FARBER/ MASS GENERAL
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240520847
Principal investigator 1 Aveo Pharmaceuticals, Inc. $21,042.00 01/08/2025 Non-covered Recipient Entity
Dana Farber Cancer Institute
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199911293